{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:14:28Z","timestamp":1792599268456,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Low-density lipoprotein cholesterol (LDL-C) testing and the use of lipid-lowering therapies (LLTs) both reduce risk in patients with atherosclerotic cardiovascular disease (ASCVD). This study aims to assess LDL-C testing and the utilization of LLT in a diverse real-world cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This retrospective cohort study assessed 6405 patients who underwent percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), or a peripheral artery disease (PAD) revascularization between 2018 and 2023 at a New York City health system. Patient-level data were extracted from the electronic health record. Multivariable logistic regression analyses were employed to evaluate associations. Overall, 4319 patients (67%) had a follow-up LDL-C test. The median time to follow-up LDL-C testing was 11 months, with 35% having follow-up testing within 6 months. Early LDL-C testing (within 6 months) was associated with higher utilization of high-intensity statins, ezetimibe, and proprotein convertase subtilisin\/kexin type 9 inhibitors (PCSK9i) monoclonal antibodies (mAbs). At follow-up, 2259 (52%) patients had an LDL-C &amp;lt; 70\u2005mg\/dL (1.8\u2005mmol\/L). Female sex (odds ratio [OR] 0.70; 95% confidence interval [CI] 0.61, 0.80) and non-Hispanic Black race\/ethnicity (OR 0.57; 95% CI 0.49, 0.67) were independently associated with a lower likelihood of achieving a follow-up LDL-C &amp;lt; 70\u2005mg\/dL (1.8\u2005mmol\/L) after multivariable adjustment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among patients with ASCVD who underwent revascularization, a large proportion did not have follow-up LDL-C testing, and in those who did, testing was delayed. Only half of patients achieved LDL-C levels below 70\u2005mg\/dL (1.8\u2005mmol\/L), with female and non-Hispanic Black patients less likely to attain this goal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf235","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:47:28Z","timestamp":1744476448000},"page":"1192-1201","source":"Crossref","is-referenced-by-count":10,"title":["Disparities in achieving low-density lipoprotein cholesterol goals after revascularization in a diverse real-world cohort"],"prefix":"10.1093","volume":"32","author":[{"given":"Garred S","family":"Greenberg","sequence":"first","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-167X","authenticated-orcid":false,"given":"Daniel","family":"Lorenzatti","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Filtz","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita N","family":"Jaspan","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Kalich","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Kathe","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Sidelnikov","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH , Rotkreuz ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E","family":"Di Palo","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Montefiore Health System\/Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Browne","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lipsitz","sequence":"additional","affiliation":[{"name":"Vascular Surgery Division, Montefiore Medical Center\/Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forest","sequence":"additional","affiliation":[{"name":"Cardiothoracic Surgery Division, Montefiore Medical Center\/Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scotti","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeem","family":"Latib","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario J","family":"Garcia","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos J","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine , Winston-Salem, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[{"name":"The Barbra Streisand Women\u2019s Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center , Los Angeles, CA ,","place":["USA"]},{"name":"The Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-3735","authenticated-orcid":false,"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[{"name":"Cardiology Division, Montefiore Health System\/Albert Einstein College of Medicine , 111 East 210th Street, Bronx, NY 10467 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2025092119522722200_zwaf235-B1","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/eurjpc\/zwad111","article-title":"Efficacy and safety of low levels of low-density lipoprotein cholesterol: trans-ancestry linear and non-linear Mendelian randomization analyses","volume":"30","author":"Liu","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522722200_zwaf235-B3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurjpc\/zwae349","article-title":"Impact of cumulative LDL cholesterol and other risk factors on coronary artery disease prevalence in patients with familial hypercholesterolaemia","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522722200_zwaf235-B4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/jpet.123.001878","article-title":"Long-lasting control of LDL cholesterol induces a 40% reduction in the incidence of cardiovascular events: new insights from a 7-year study","volume":"388","author":"Trimarco","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"2025092119522722200_zwaf235-B5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2025092119522722200_zwaf235-B6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S2213-8587(22)00043-2","article-title":"Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"10","author":"Ostadal","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025092119522722200_zwaf235-B7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025092119522722200_zwaf235-B8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2025092119522722200_zwaf235-B9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025092119522722200_zwaf235-B10","first-page":"195","article-title":"Bempedoic acid: an emerging therapy for uncontrolled low-density lipoprotein (LDL) cholesterol","volume":"10","author":"Pradhan","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025092119522722200_zwaf235-B11","first-page":"429","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"75","author":"Visseren","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025092119522722200_zwaf235-B12","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025092119522722200_zwaf235-B14","doi-asserted-by":"crossref","first-page":"100753","DOI":"10.1016\/j.jacadv.2023.100753","article-title":"Low-density lipoprotein cholesterol testing following myocardial infarction hospitalization among medicare beneficiaries","volume":"3","author":"Colantonio","year":"2024","journal-title":"JACC Adv"},{"key":"2025092119522722200_zwaf235-B15","doi-asserted-by":"crossref","first-page":"e009251","DOI":"10.1161\/JAHA.118.009251","article-title":"Measurement of low-density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM registry","volume":"7","author":"Lowenstern","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025092119522722200_zwaf235-B16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","article-title":"Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification","volume":"135","author":"Rana","year":"2022","journal-title":"Am J Med"},{"key":"2025092119522722200_zwaf235-B17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S361258","article-title":"Lipid testing trends before and after hospitalization for myocardial infarction among adults in the United States, 2008\u20132019","volume":"14","author":"Levintow","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2025092119522722200_zwaf235-B18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025092119522722200_zwaf235-B19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522722200_zwaf235-B20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamacardio.2023.0228","article-title":"Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020","volume":"8","author":"Jacobs","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025092119522722200_zwaf235-B21","doi-asserted-by":"crossref","first-page":"117268","DOI":"10.1016\/j.atherosclerosis.2023.117268","article-title":"Sex differences in the management of atherosclerotic cardiovascular disease","volume":"384","author":"Holtzman","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025092119522722200_zwaf235-B22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIR.0000000000000071","article-title":"Status of cardiovascular disease and stroke in Hispanics\/Latinos in the United States","volume":"130","author":"Rodriguez","year":"2014","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s40615-016-0283-3","article-title":"Discrepancies in race and ethnicity documentation: a potential barrier in identifying racial and ethnic disparities","volume":"4","author":"Maga\u00f1a L\u00f3pez","year":"2016","journal-title":"J Racial Ethn Health Disparities"},{"key":"2025092119522722200_zwaf235-B24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/CIR.0000000000001139","article-title":"Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association","volume":"147","author":"Mehta","year":"2023","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12933-020-01125-1","article-title":"Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes","volume":"19","author":"Jin","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2025092119522722200_zwaf235-B26","first-page":"342","article-title":"Comparison of estimated LDL cholesterol equations with direct measurement in patients with angiographically confirmed coronary artery disease","volume":"9","author":"Shi","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025092119522722200_zwaf235-B27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12916-022-02633-5","article-title":"Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events","volume":"20","author":"Sakuma","year":"2022","journal-title":"BMC Med"},{"key":"2025092119522722200_zwaf235-B28","doi-asserted-by":"crossref","first-page":"zwae175.363","DOI":"10.1093\/eurjpc\/zwae175.363","article-title":"LDL-C target attainment in the secondary prevention of atherosclerotic cardiovascular disease in Albania: barriers and strategies to reach the goals","volume":"31","author":"Rrapo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522722200_zwaf235-B29","doi-asserted-by":"crossref","first-page":"zwab061.406","DOI":"10.1093\/eurjpc\/zwab061.406","article-title":"Attainment of the 2019 ESC\/EAS recommended LDL-C goal in Greek patients with established atherosclerotic cardiovascular disease","volume":"28","author":"Ioannidis","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522722200_zwaf235-B30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12933-024-02386-w","article-title":"Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial","volume":"23","author":"Hong","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2025092119522722200_zwaf235-B31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/eurjpc\/zwaa088","article-title":"The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort","volume":"28","author":"Blaum","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522722200_zwaf235-B32","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522722200_zwaf235-B33","first-page":"46","article-title":"Quality control to improve LDL-cholesterol management in patients with acute coronary syndromes based on the ACS EuroPath IV project","volume":"13","author":"Schiele","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025092119522722200_zwaf235-B34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1089\/jwh.2019.8125","article-title":"The cardiovascular disease epidemic in African American women: recognizing and tackling a persistent problem","volume":"29","author":"Ebong","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"key":"2025092119522722200_zwaf235-B35","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCULATIONAHA.118.037689","article-title":"Why are young Black women at high risk for cardiovascular disease?","volume":"139","author":"Kalinowski","year":"2019","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B36","doi-asserted-by":"crossref","first-page":"e020890","DOI":"10.1161\/JAHA.121.020890","article-title":"Racial disparities in modifiable risk factors and statin usage in Black patients with familial hypercholesterolemia","volume":"10","author":"Agarwala","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025092119522722200_zwaf235-B37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"2025092119522722200_zwaf235-B38","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jacc.2022.08.769","article-title":"Eliminating disparities in cardiovascular disease for Black women","volume":"80","author":"Ogunniyi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522722200_zwaf235-B39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIR.0000000000000381","article-title":"Preventing and experiencing ischemic heart disease as a woman: state of the science","volume":"133","author":"McSweeney","year":"2016","journal-title":"Circulation"},{"key":"2025092119522722200_zwaf235-B40","doi-asserted-by":"crossref","first-page":"117500","DOI":"10.1016\/j.atherosclerosis.2024.117500","article-title":"Closing the sex gap in cardiovascular mortality by achieving both horizontal and vertical equity","volume":"392","author":"Bugiardini","year":"2024","journal-title":"Atherosclerosis"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf235\/62941034\/zwaf235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1192\/62941034\/zwaf235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1192\/62941034\/zwaf235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:52:40Z","timestamp":1758498760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/32\/13\/1192\/8114729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf235","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,4,16]]}}}